Cassava’s Alzheimer’s Drug Fails In First Phase III, Second Pivotal Trial Stopped
SEC Settlement Overhang Remains
After years of controversy, simufilam did not achieve statistical significance on any endpoints in ReThink-ALZ, so the company ended ReFocus-ALZ and its long-term extension study.
